89401-54-7

Usage

Uses

Used in Pharmaceutical Industry:
5-Thiazolecarboxylic acid, 4-methyl-2-(4-pyridinyl)-, ethyl ester is used as a building block in organic synthesis for the development of new drugs. Its unique structural features allow for the production of various derivatives with potential bioactive properties, making it a valuable component in the creation of novel pharmaceutical compounds.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Thiazolecarboxylic acid, 4-methyl-2-(4-pyridinyl)-, ethyl ester may serve as a starting material for the development of new crop protection agents. Its structural characteristics can be utilized to create derivatives with potential pesticidal or herbicidal properties, contributing to the advancement of more effective and targeted agrochemical products.
Used in Specialty Chemicals Development:
5-Thiazolecarboxylic acid, 4-methyl-2-(4-pyridinyl)-, ethyl ester can also be employed in the development of specialty chemicals. Its versatile structure allows for the synthesis of a range of chemical compounds with specific applications in various industries, such as materials science, environmental protection, and more.
However, it is important to note that further research and testing are required to determine the specific properties and potential uses of 5-Thiazolecarboxylic acid, 4-methyl-2-(4-pyridinyl)-, ethyl ester in these industries.

Upstream product

• 2196-13-6 pyridine-4-carbothioamide 
• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 

Downstream Products

• 144060-98-0 4-methyl-2-(4-pyridinyl)-1,3-thiazole-5-carboxylic acid 

Relevant academic research and scientific papers

Synthesis and characterizations of novel thiazolyl-thiadiazole derivatives as telomerase activators

Pyridine-3/4-thiocarboxamide derivatives were used as starting materials for the synthesis of the target compounds. The pyridine-3/4-thiocarboxamide derivatives were reacted with ethyl 2-chloroacetoacetate in ethanol to give the thiazole derivatives (1, 2). The two ethyl thiazole-carboxylate derivatives (1, 2) thus obtained were treated with sodium hydroxide solution and ethanol and converted to carboxylic acids (3, 4). The carboxylic acid derivatives (3, 4) were reacted with thiosemicarbazide in phosphoroxy trichloride and aminothiadiazole rings (5, 6) were formed. Thus, two thiazolyl-thiadiazole amine derivatives (5, 6) were obtained. These two derivatives (5, 6) were converted into two chloroacetamidothiadiazole derivatives (7, 8) by reaction with chloroacetylchloride over the amino group in the presence of triethylamine in acetone. After all these steps, the starting materials (7, 8) needed to reach the target compounds were obtained. With the two derivatives (7, 8) obtained in this last step, phenol and thiophenol derivatives were reacted in acetone in the presence of potassium carbonate. The target compounds, thiazolyl-thiadiazole derivatives (TDA1?16), are completely unique and their structure has been elucidated by elemental analysis, IR, NMR, and MS spectral data. After all these synthesis steps, telomerase activity studies were performed on the target compounds obtained. For this purpose, a PCR ELISA-based TRAP method was used on the heart of zebrafish. According to the enzyme assay results, derivative TDA8 has shown an increase of telomerase enzyme activity.

Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors

The Cell division cycle 7 (Cdc7) protein kinase is essential for DNA replication and maintenance of genome stability. We systematically explored thiazole-based compounds as inhibitors of Cdc7 kinase activity in cancer cells. Our studies resulted in the identification of a potent, selective Cdc7 inhibitor that decreased phosphorylation of the direct substrate MCM2 in vitro and in vivo, and inhibited DNA synthesis and cell viability in vitro.

Sulfonamide derivatives, their production and use

The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. Compounds of this invention are piperazinones of the formula: wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, in addition to being substituted by the group of the formula: and the group of the formula: Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent heterocyclic group; X is a direct bond or an optionally substituted alkylene chain; Z is (1) an amino group substituted with an optionally substituted hydrocarbon group, (2) an optionally substituted imino group or (3) an optionally substituted nitrogen-containing heterocyclic group; provided that when X is a direct bond and Z is an optionally substituted 6-membered nitrogen-containing aromatic heterocyclic group, Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent unsaturated heterocyclic group; or a salt thereof.

Benzamidine derivatives

Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.